Results 81 to 90 of about 29,074 (242)

Homogeneous Bispecifics by Disulfide Bridging

Bioconjugate Chemistry, 2014
We report on a chemical platform to generate site-specific, homogeneous, antibody-antibody conjugates by targeting and bridging disulfide bonds. A bispecific antibody construct was produced in good yield through simple reduction and bridging of antibody fragment disulfide bonds, using a readily synthesized bis-dibromomaleimide cross-linker.
Hull, EA, Livanos, M, Miranda, E, Smith, ME, Chester, KA, Baker, JR   +5 more
openaire   +3 more sources

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

Augmented emicizumab-driven coagulation potential in hemophilia A state by in vitro and in vivo supplementation of combined factors IX and X

Research and Practice in Thrombosis and Haemostasis
Background: Persons with hemophilia A (HA) and inhibitors undergoing emicizumab prophylaxis require bypassing agents when breakthrough bleeding occurs.
Mitsumasa Osuna, Yuto Nakajima, Eisuke Takami, Hirotoshi Nakano, Keiji Nogami   +4 more
doaj   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions

mAbs
The development of bispecific antibodies that bind at least two different targets relies on bringing together multiple binding domains with different binding properties and biophysical characteristics to produce a drug-like therapeutic.
Michael Mullin, James McClory, Winston Haynes, Justin Grace, Nathan Robertson, Gino van Heeke   +5 more
doaj   +1 more source

Tolerability and efficacy of chemosaturation in combination with systemic therapy for metastatic uveal melanoma

International Journal of Cancer, EarlyView.
What's New? Uveal melanoma is the most common primary intraocular cancer in adults, and up to half of patients develop metastatic disease, predominantly in the liver, where prognosis remains poor despite promising treatment options. In this study, the authors evaluated the safety and efficacy of administering systemic therapy within 40 days of liver ...
Patrick Kasteleiner, Gerd Grözinger, Jörg Schmehl, Lukas Flatz, Andrea Forschner   +4 more
wiley   +1 more source

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release

mAbs
T cell engagers (TCEs) are becoming an integral class of biological therapeutic owing to their highly potent ability to eradicate cancer cells. Nevertheless, the widespread utility of classical CD3-targeted TCEs has been limited by narrow therapeutic ...
John S. Schardt, Even Walseng, Kim Le, Chunning Yang, Pooja Shah, Ying Fu, Kausar Alam, Cathryn R. Kelton, Yu Gu, Fengying Huang, Jia Lin, Wenhai Liu, Andrew Dippel, Hanzhi Zhang, Kathy Mulgrew, Stacy Pryts, Vijaykumar Chennupati, Hung-Chang Chen, Jessica Denham, Xiaoru Chen, Pallab Pradhan, Yuling Wu, Colin Hardman, Chihao Zhao, Michael Kierny, Yang Song, Simon J. Dovedi, Saso Cemerski, Yariv Mazor   +28 more
doaj   +1 more source

The T‐Cell Response Mechanism in Human Papillomavirus‐Associated Cervical Cancer and New Strategies for Immunotherapy

iNew Medicine, EarlyView.
ABSTRACT Human papillomavirus (HPV) is a double‐stranded DNA virus that infects human skin and mucosal tissues exclusively. The German scientist Harald zur Hausen was awarded the 2008 Nobel Prize in Physiology or Medicine for his discovery of the link between HPV infection and cervical cancer.
Fang Zhu, Farah Nazir, Ying Zhou, Yuhua Shang, Hongliang He, Tengchuan Jin   +5 more
wiley   +1 more source

Developability considerations for bispecific and multispecific antibodies

mAbs
Bispecific antibodies (bsAb) and multispecific antibodies (msAb) encompass a diverse variety of formats that can concurrently bind multiple epitopes, unlocking mechanisms to address previously difficult-to-treat or incurable diseases. Early assessment of
Alaa Amash, Gesa Volkers, Patrick Farber, Daniel Griffin, K. Shawn Davison, Allison Goodman, Raffi Tonikian, Aaron Yamniuk, Bryan Barnhart, Tim Jacobs   +9 more
doaj   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source